Volltext-Downloads (blau) und Frontdoor-Views (grau)
The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 14 of 134
Back to Result List

Bitte verwenden Sie diesen Link, wenn Sie dieses Dokument zitieren oder verlinken wollen: https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-63720

Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial

  • Postoperative restenosis in patients with external ear canal (EEC) atresia or stenosis is a common complication following canaloplasty. Our aim in this study was to explore the feasibility of using a three dimensionally (3D)-printed, patient-individualized, drug ((dexamethasone (DEX)), and ciprofloxacin (cipro))-releasing external ear canal implant (EECI) as a postoperative stent after canaloplasty. We designed and pre-clinically tested this novel implant for drug release (by high-performance liquid chromatography), biocompatibility (by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay), bio-efficacy (by the TNF-α (tumor necrosis factor-alpha)-reduction test (DEX) and inhibition zone test (for cipro)), and microbial contamination (formation of turbidity or sediments in culture medium). The EECI was implanted for the first time to one patient with a history of congenital EEC atresia and state after three canaloplasties due to EEC restenosis. The preclinical tests revealed no cytotoxic effect of the used materials; an antibacterial effect was verified against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, and the tested UV-irradiated EECI showed no microbiological contamination. Based on the test results, the combination of silicone with 1% DEX and 0.3% cipro was chosen to treat the patient. The EECI was implantable into the EEC; the postoperative follow-up visits revealed no otogenic symptoms or infections and the EECI was explanted three months postoperatively. Even at 12 months postoperatively, the EEC showed good epithelialization and patency. Here, we report the first ever clinical application of an individualized, drug-releasing, mechanically flexible implant and suggest that our novel EECI represents a safe and effective method for postoperatively stenting the reconstructed EEC.

Download full text files

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author: Farnaz Matin-Mann, Ziwen Gao, Jana Schwieger, Martin Ulbricht, Vanessa Domsta, Stefan Senekowitsch, Werner WeitschiesORCiD, Anne Seidlitz, Katharina Doll, Meike Stiesch, Thomas Lenarz, Verena Scheper
URN:urn:nbn:de:gbv:9-opus-63720
DOI:https://doi.org/10.3390/pharmaceutics14061242
ISSN:1999-4923
Parent Title (English):Pharmaceutics
Publisher:MDPI
Place of publication:Basel
Editor: Dimitrios G. Fatouros
Document Type:Article
Language:English
Date of first Publication:2022/06/11
Release Date:2022/11/16
Tag:additive manufacturing; drug-eluting implant; ear canal stenosis; external auditory canal; personalized implant; preoperative workflow
GND Keyword:-
Volume:14
Issue:6
Faculties:Universitätsmedizin / Institut für Pharmakologie
Licence (German):License LogoCreative Commons - Namensnennung